PIM
VRTX icon

Provident Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Provident Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9M Sell
140,728
-6,892
-5% -$3.05M 6.79% 3
2026
Q1 		$65.9M Sell
147,620
-1,638
-1% -$764K 6.55% 2
2025
Q4 		$67.7M Sell
149,258
-4,148
-3% -$1.79M 6.16% 4
2025
Q3 		$60.1M Sell
153,406
-5,301
-3% -$2.22M 5.3% 4
2025
Q2 		$70.7M Buy
158,707
+2,382
+2% +$1.1M 6.04% 4
2025
Q1 		$75.8M Buy
156,325
+1,259
+0.8% +$587K 7.14% 2
2024
Q4 		$62.4M Sell
155,066
-439
-0.3% -$203K 5.96% 7
2024
Q3 		$72.3M Sell
155,505
-4,357
-3% -$2.09M 6.45% 3
2024
Q2 		$74.9M Sell
159,862
-263
-0.2% -$114K 6.82% 3
2024
Q1 		$66.9M Sell
160,125
-194
-0.1% -$82K 5.9% 5
2023
Q4 		$65.2M Sell
160,319
-850
-0.5% -$314K 6.16% 4
2023
Q3 		$56M Sell
161,169
-1,060
-0.7% -$371K 6.18% 5
2023
Q2 		$57.1M Sell
162,229
-815
-0.5% -$275K 6.04% 4
2023
Q1 		$51.4M Buy
163,044
+2,317
+1% +$695K 5.57% 5
2022
Q4 		$46.4M Sell
160,727
-1,300
-0.8% -$396K 5.5% 5
2022
Q3 		$46.9M Sell
162,027
-7,328
-4% -$2.11M 6.01% 3
2022
Q2 		$47.7M Sell
169,355
-17,959
-10% -$4.81M 5.62% 4
2022
Q1 		$48.9M Buy
187,314
+2,135
+1% +$507K 4.68% 9
2021
Q4 		$40.7M Buy
185,179
+1,813
+1% +$353K 3.67% 16
2021
Q3 		$33.3M Buy
183,366
+6,531
+4% +$1.28M 3.18% 20
2021
Q2 		$35.7M Buy
+176,835
New +$37M 3.44% 19

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Provident Investment Management's VRTX Position: Q2 2026 in Review

Provident Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q2 2026, selling an estimated $3.05M and leaving 140,728 shares worth $69.9M. The position accounts for 6.79% of the portfolio, ranked #3.

Provident Investment Management first reported a position in VRTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $75.8M in Q1 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Provident Investment Management held 140,728 shares of Vertex Pharmaceuticals worth $69.9M as of Q2 2026.
  • Provident Investment Management sold 6,892 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.05M.
  • Vertex Pharmaceuticals made up 6.79% of Provident Investment Management's portfolio in Q2 2026, its #3 holding.
  • Provident Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Provident Investment Management's Vertex Pharmaceuticals position peaked at $75.8M in Q1 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Provident Investment Management's 13F filing for Q2 2026, filed 11 Aug 2026.